Cochrane · systematic review · CD013825
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
Kreuzberger, N, Hirsch, C, Chai, KL, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
54
current version
GRADE rated
31
No studies
23
Included studies
NR
No studies 23 · 42.6%Ungraded 0 · 0%Very low 1 · 1.9%Low 27 · 50%Moderate 3 · 5.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)
Population: non‐hospitalised individuals with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Bamlanivimab vs placebo | no estimate extracted | 1 study · 101 participants | Low Downgraded: imprecision |
Mortality by day 60 Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Clinical progression/improvement of symptoms Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Quality of life Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Admission to hospital by day 30 Bamlanivimab vs placebo | RR 0.17 [0.02, 1.33] | 1 study · 257 participants | Low Downgraded: imprecision |
 Bamlanivimab vs placebo | RR 0.32 [0.07, 1.47] | 1 study · 263 participants | Low Downgraded: imprecision |
Adverse events: all grades Bamlanivimab vs placebo | RR 0.99 [0.66, 1.5] | 1 study · 257 participants | Low Downgraded: imprecision |
Serious adverse events Bamlanivimab vs placebo | RR 0.51 [0.02, 12.47] | 1 study · 257 participants | Low Downgraded: imprecision |
Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Population: non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Bamlanivimab/etesevimab vs placebo | RR 0.05 [0, 0.81] | 1 study · 1035 participants | Low Downgraded: imprecision |
Mortality by day 60 ‐ not reported Bamlanivimab/etesevimab vs placebo | no estimate extracted | NR | No studies |
Clinical progression Bamlanivimab/etesevimab vs placebo | no estimate extracted | NR | No studies |
Quality of life by day 30 Bamlanivimab/etesevimab vs placebo | no estimate extracted | NR | No studies |
Admission to hospital or death Bamlanivimab/etesevimab vs placebo | RR 0.3 [0.16, 0.59] | 1 study · 1035 participants | Low Downgraded: imprecision |
Adverse events: all grades Bamlanivimab/etesevimab vs placebo | RR 1.15 [0.83, 1.59] | 1 study · 1035 participants | Low Downgraded: imprecision |
Serious adverse events Bamlanivimab/etesevimab vs placebo | RR 1.4 [0.45, 4.37] | 1 study · 1035 participants | Low Downgraded: imprecision |
Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)
Population: non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Mortality by day 60 Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Quality of life Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Admission to hospital or death Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 3‐4 Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: all grades Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Serious adverse events Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Population: non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Sotrovimab vs placebo | RR 0.33 [0.01, 8.18] | 1 study · 583 participants | Low Downgraded: imprecision |
Mortality by day 60 Sotrovimab vs placebo | no estimate extracted | NR | No studies |
Clinical progression: oxygen requirement (≥ 5 WHO scale) Sotrovimab vs placebo | RR 0.11 [0.02, 0.45] | 1 study · 583 participants | Low Downgraded: imprecision |
Clinical progression: IMV or death (≥ 7 WHO scale) Sotrovimab vs placebo | RR 0.14 [0.01, 2.76] | 1 study · 583 participants | Low Downgraded: imprecision |
Quality of life by day 30 Sotrovimab vs placebo | no estimate extracted | NR | No studies |
Admission to hospital or death by day 30 Sotrovimab vs placebo | RR 0.14 [0.04, 0.48] | 1 study · 583 participants | Low Downgraded: imprecision |
Adverse events: all grades Sotrovimab vs placebo | RR 0.87 [0.66, 1.16] | 1 study · 868 participants | Low Downgraded: imprecision |
Adverse events: grades 3 and 4 Sotrovimab vs placebo | RR 0.26 [0.12, 0.6] | 1 study · 868 participants | Low Downgraded: imprecision |
Serious adverse events Sotrovimab vs placebo | RR 0.27 [0.12, 0.63] | 1 study · 868 participants | Low Downgraded: imprecision |
Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Population: non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30Â Regdanvimab vs placebo | no estimate extracted | 1 study · 1 participants | Low Downgraded: imprecision |
Mortality by day 60Â Regdanvimab vs placebo | no estimate extracted | NR | No studies |
Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV) Regdanvimab vs placebo | no estimate extracted | 1 study · 1 participants | Low Downgraded: imprecision |
Quality of life by day 30 Regdanvimab vs placebo | no estimate extracted | NR | No studies |
Admission to hospital or death by day 30Â Regdanvimab vs placebo | RR 0.45 [0.14, 1.42] | 1 study · 204 participants | Low Downgraded: imprecision |
Adverse events: all grades Regdanvimab vs placebo | RR 0.96 [0.64, 1.43] | 1 study · 215 participants | Low Downgraded: imprecision |
Adverse events: grades 3 and 4 Regdanvimab vs placebo | RR 2.62 [0.52, 13.12] | 1 study · 215 participants | Low Downgraded: imprecision |
Serious adverse events by day 30 Regdanvimab vs placebo | no estimate extracted | 1 study · 1 participants | Low Downgraded: imprecision |
Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)
Population: hospitalised individuals with COVID‐19 (moderate to severe disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Bamlanivimab vs placebo | RR 1.39 [0.4, 4.83] | 1 study · 314 participants | Low Downgraded: imprecision |
Mortality by day 90 Bamlanivimab vs placebo | HR 1.09 [0.49, 2.43] | 1 study · 314 participants | Low Downgraded: imprecision |
Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) Bamlanivimab vs placebo | RR 1.17 [0.75, 1.85] | 1 study · 311 participants | Very low Downgraded: imprecision |
Quality of life Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Time to hospital discharge up to 26.10.2020, absolute effects for day 10 Bamlanivimab vs placebo | HR 0.97 [0.76, 1.18] | 1 study · 314 participants | Low Downgraded: imprecision |
Adverse events: grades 3 and 4 by day 30 Bamlanivimab vs placebo | RR 1.27 [0.81, 1.98] | 1 study · 314 participants | Low Downgraded: imprecision |
Serious adverse events by day 30 Bamlanivimab vs placebo | RR 0.93 [0.27, 3.14] | 1 study · 314 participants | Low Downgraded: imprecision |
Casirivimab/imdevimab compared to usual care alone in hospitalised individuals with COVID‐19 (moderate to severe disease)
Population: hospitalised individuals with COVID‐19 (moderate to severe disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality by day 30 Casirivimab/imdevimab vs usual care alone | RR 0.94 [0.87, 1.02] | 1 study · 9785 participants | Moderate Downgraded: risk of bias |
Mortality by day 60 Casirivimab/imdevimab vs usual care alone | no estimate extracted | NR | No studies |
Clinical progression: need for IMV or death (WHO ≥ 7) Casirivimab/imdevimab vs usual care alone | RR 0.96 [0.9, 1.04] | 1 study · 9198 participants | Moderate Downgraded: risk of bias |
Quality of life Casirivimab/imdevimab vs usual care alone | no estimate extracted | NR | No studies |
Hospital discharge alive by day 30 Casirivimab/imdevimab vs usual care alone | RR 1.01 [0.98, 1.04] | 1 study · 9785 participants | Moderate Downgraded: risk of bias |
Adverse events: grades 3 and 4 by day 30 Casirivimab/imdevimab vs usual care alone | no estimate extracted | NR | No studies |
Serious adverse events by day 30 Casirivimab/imdevimab vs usual care alone | no estimate extracted | NR | No studies |